



**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)

Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## My treatment calendar

Helping you keep track of the SARCLISA treatment combination that you have been prescribed



# Stay on track with your SARCLISA treatment

Fill out this calendar with your doctor or nurse at your next appointment



SARCLISA is given by a doctor or nurse by intravenous (IV) infusion into your vein in 4-week, or 28-day, treatment periods called cycles. SARCLISA is given in combination with other medicines described below.

- For the first cycle, SARCLISA is usually given once a week
- After the first cycle, SARCLISA is usually given once every 2 weeks

## Other medicines given with SARCLISA

SARCLISA is given together with either Kyprolis® (carfilzomib) and dexamethasone or Pomalyst® (pomalidomide) and dexamethasone. These are other medicines that are used to treat multiple myeloma.

Kyprolis is given by IV infusion. Pomalyst is taken by mouth. Dexamethasone can either be given by IV infusion or taken by mouth.

Once you have been prescribed SARCLISA, your doctor will explain how and when you will receive SARCLISA in combination with other medicines.

My oncologist, infusion clinic, or hospital contact:

## What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.

It is not known if SARCLISA is safe and effective in children.

## Important Safety Information

**Do not receive SARCLISA if** you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full [Prescribing Information](#)).



# My SARCLISA treatment calendar

Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
My SARCLISA combination:						
Directions from my doctor or nurse:						



Fill out this calendar together with your doctor or nurse. It can help you keep track of appointment times and reminders for the medicines you may take at home.


[illegible]

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**






This image shows a full page of blank, lined paper. It features approximately 20 evenly spaced horizontal grey lines across its entire width, providing a guide for handwriting or typing. The paper itself is a clean, off-white color.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

**Directions from my doctor or nurse:**




[illegible]

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**




[illegible]

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**




[illegible]

  
**SARCLISA®**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

**Directions from my doctor or nurse:**






This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

  
**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL

## Month:

[illegible]

**Directions from my doctor or nurse:**





## Notes and questions

Use this space to write down additional questions you may have or information you want to share with your healthcare team.

[illegible]

**Please see Important Safety Information on inside back cover,  
and accompanying full Prescribing Information, including  
Patient Information.**

**SARCLISA<sup>®</sup>**  
(isatuximab-irfc)  
Injection for intravenous use  
500 mg/25 mL, 100 mg/5 mL



Important Safety Information (cont'd)

- Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:**
- Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
  - Have had shingles (herpes zoster)
  - Are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
    - Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
- Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**How will I receive SARCLISA?**

- SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
- SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone.
  - In cycle 1, SARCLISA is usually given weekly.
  - Starting in cycle 2, SARCLISA is usually given every 2 weeks.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
- Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

**What are the possible side effects of SARCLISA?**

**SARCLISA may cause serious side effects, including:**

- **Infusion reactions.** Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
  - Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
  - Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.

**Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:**

- |   |                        |
|---|------------------------|
| – shortness of breath, wheezing, or trouble breathing | – headache             |
| – swelling of the face, mouth, throat, or tongue      | – cough                |
| – throat tightness                                    | – rash or itching      |
| – palpitations  | – nausea               |
| – dizziness, lightheadedness, or fainting             | – runny or stuffy nose |
|   | – chills               |

- **Decreased white blood cell counts.** Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory tract infections and urinary tract infections.

Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

**Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.**
- **Risk of new cancers.** New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
- **Change in blood tests.** SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. **Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.**

**The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:**

- upper respiratory tract infection
- lung infection (pneumonia)
- diarrhea
- decreased red blood cell count (anemia)
- decreased platelet count (thrombocytopenia)

**The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:**

- |                                     |   |
|-------------------------------------|---|
| • upper respiratory tract infection | • trouble sleeping                            |
| • tiredness and weakness            | • bronchitis                                  |
| • high blood pressure               | • cough                                       |
| • diarrhea                          | • back pain                                   |
| • lung infection (pneumonia)        | • decreased red blood cell count (anemia)     |
| • trouble breathing                 | • decreased platelet count (thrombocytopenia) |


Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. **Tell your healthcare provider right away if you develop any of the following symptoms:**

- trouble breathing
- cough
- swelling of your ankles, feet, or legs

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see Important Safety Information on inside back cover, and accompanying full Prescribing Information, including Patient Information.





The CareASSIST Patient Support Program helps eligible patients with access and support for SARCLISA.

Learn more at [SanofiCareAssist.com/sarclisa](https://SanofiCareAssist.com/sarclisa).



Scan with your  
smartphone  
camera

**sanofi**

Kyprolis is a registered trademark of Amgen, Inc.  
Pomalyst is a registered trademark of Celgene Corporation.  
SARCLISA and Sanofi are registered in the U.S. Patent and Trademark Office.  
© 2022 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2014088-v3.0 08/2022